Lida R Tehrani

USPTO Granted Patents = 25 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 11.0

ph-index = 7

Forward Citations = 261(Granted Patents)

Location History:

San Diego, NJ (US) (2008)
San Diego, CA (US) (2006 - 2023)

Company Filing History:

13 out of 169

Signal Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

patents

Years Active: 2006-2025

Loading Chart...

25 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12227490 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2025-02-18),

2. 12103920 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2024-10-01),

3. 11739075 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-08-29),

4. 11634407 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-04-25),

5. 11560371 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith (2023-01-24),

6. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),

7. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),

8. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),

9. 9795607 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2017-10-24),

10. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),

11. 9428509 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-08-30),

12. 9346812 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-05-24),

13. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway (2013-08-13),

14. 8492381 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway (2013-07-23),

15. 8372976 - Methods of treatment comprising the administration of heteroaryl compounds (2013-02-12),

Title: Innovations of Lida R Tehrani: A Pioneer in Androgen Receptor Research

Introduction: Lida R Tehrani is an accomplished inventor based in San Diego, NJ, renowned for his contributions to pharmaceutical innovations. With a prolific portfolio of 25 patents, Tehrani is recognized for his significant advancements in the field of medical treatment, particularly through his work on compounds targeting androgen receptor-mediated diseases.

Latest Patents: Among his latest patents are groundbreaking inventions related to "Cereblon binding compounds, compositions thereof, and methods of treatment therewith." These innovations include piperidine dione compounds designed to offer effective treatments for conditions influenced by androgen receptors. His work outlines the structure and potential applications of these compounds, showcasing their importance in the medical field.

Career Highlights: Lida R Tehrani has left a mark on leading pharmaceutical companies, including Signal Pharmaceuticals, Inc. and Merck & Company, Inc. His tenure at these prestigious organizations has enabled him to refine his expertise in drug discovery and development, contributing to the emergence of novel therapeutic agents.

Collaborations: Throughout his career, Tehrani has collaborated with notable colleagues such as John J Sapienza and Dehua Huang. These professional relationships have facilitated the exchange of innovative ideas and fostered advancements in their respective fields.

Conclusion: Lida R Tehrani's dedication to innovation in pharmaceutical research is evident through his numerous patents and collaborative efforts. His ongoing work not only enhances the understanding of complex diseases but also significantly contributes to the development of effective treatments, promising a brighter future for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.